---
document_datetime: 2025-12-29 12:46:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/firazyr.html
document_name: firazyr.html
version: success
processing_time: 0.4299055
conversion_datetime: 2025-12-30 21:17:38.009353
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Firazyr

[RSS](/en/individual-human-medicine.xml/66029)

##### Authorised

This medicine is authorised for use in the European Union

icatibant Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Firazyr](#news-on)
- [More information on Firazyr](#more-information-on-firazyr-591)
- [Product information - with tracked changes](#product-information-with-tracked-changes-80196)
- [More information on Firazyr](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Firazyr. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Firazyr.

For practical information about using Firazyr, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Firazyr and what is it used for?

Firazyr is a medicine used to treat the symptoms of attacks of hereditary angioedema in adults, adolescents and children aged over 2 years. Patients with angioedema have attacks of swelling that can occur anywhere in the body, such as in the face or limbs, or around the gut, causing discomfort and pain. Attacks of hereditary angioedema can be life threatening when they involve the throat. Firazyr is used in patients whose angioedema is linked to naturally low levels of a protein called 'C1 esterase inhibitor'.

Firazyr contains the active substance icatibant.

Because the number of patients with angioedema is low, the disease is considered 'rare', and Firazyr was designated an 'orphan medicine' (a medicine used in rare diseases) on 17 February 2003.

## How is Firazyr used?

Each pre-filled syringe of Firazyr contains 30 mg icatibant in 3 ml. The medicine is given by injecting it slowly under the skin, preferably in the abdomen (belly). The recommended dose of Firazyr in adults is one injection (3 ml). If symptoms continue or come back, a second injection can be given after 6 hours. If needed, treatment can be repeated for a third time after an additional 6 hours. No more than three injections should be given in any 24-hour period.

The dose for adolescents and children depends on their body weight.

The doctor may decide that the patient or their caregiver can inject the medicine themselves, after they have been properly trained by a healthcare professional.

Firazyr can only be obtained with a prescription. For further information, see the package leaflet.

## How does Firazyr work?

Patients with hereditary angioedema have high levels of a substance called 'bradykinin', which is involved in causing inflammation and swelling. The active substance in Firazyr, icatibant, blocks the receptors that bradykinin normally attaches to. This blocks the activity of bradykinin, helping to relieve the symptoms of the disease.

## What benefits of Firazyr have been shown in studies?

Firazyr was found effective in two main studies in adults with hereditary angioedema involving the skin or the abdomen. The main measure of effectiveness was how long it took for the patient's symptoms to be relieved. In both studies, the time it took for symptoms to improve was shorter for patients taking Firazyr than the comparator medicine.

The first study compared Firazyr with tranexamic acid (another medicine for hereditary angioedema) in 74 patients, and the second study compared Firazyr with placebo (a dummy treatment) in 56 patients. Patients' symptoms were relieved on average 2 to 2.5 hours after receiving Firazyr, compared with 12 hours for tranexamic acid in one study and 4.6 hours for placebo in the other study. Firazyr was also found effective among patients included in the two studies who had attacks of angioedema that affected the throat.

In another study involving 22 adolescents and children aged over 2 years with hereditary angioedema, symptoms improved on average 1 hour after the patients received Firazyr.

## What are the risks associated with Firazyr?

The most common side effects with Firazyr (seen in more than 1 patient in 10) are injection site reactions including erythema (redness), swelling, burning, itching and pain at injection sites.

For the list of all side effects and restrictions with Firazyr, see the package leaflet.

## Why is Firazyr approved?

The European Medicines Agency decided that Firazyr's benefits are greater than its risks and recommended that it be given marketing authorisation.

Firazyr was found to relieve swelling in the skin and abdomen, as well as swelling of the throat. It works in a different way to other authorised treatments.

## What measures are being taken to ensure the safe and effective use of Firazyr?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Firazyr have been included in the summary of product characteristics and the package leaflet.

## Other information about Firazyr

The European Commission granted a marketing authorisation valid throughout the European Union for Firazyr on 11 July 2008.

For more information about treatment with Firazyr, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Firazyr : EPAR - Summary for the public

English (EN) (77.45 KB - PDF)

**First published:** 14/07/2008

**Last updated:** 06/12/2017

[View](/en/documents/overview/firazyr-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-806)

български (BG) (104.13 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/bg/documents/overview/firazyr-epar-summary-public_bg.pdf)

español (ES) (77.37 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/es/documents/overview/firazyr-epar-summary-public_es.pdf)

čeština (CS) (103.21 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/cs/documents/overview/firazyr-epar-summary-public_cs.pdf)

dansk (DA) (77 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/da/documents/overview/firazyr-epar-summary-public_da.pdf)

Deutsch (DE) (78.39 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/de/documents/overview/firazyr-epar-summary-public_de.pdf)

eesti keel (ET) (75.94 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/et/documents/overview/firazyr-epar-summary-public_et.pdf)

ελληνικά (EL) (104.84 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/el/documents/overview/firazyr-epar-summary-public_el.pdf)

français (FR) (77.79 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/fr/documents/overview/firazyr-epar-summary-public_fr.pdf)

hrvatski (HR) (97.17 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/hr/documents/overview/firazyr-epar-summary-public_hr.pdf)

italiano (IT) (76.51 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/it/documents/overview/firazyr-epar-summary-public_it.pdf)

latviešu valoda (LV) (98.52 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/lv/documents/overview/firazyr-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (100.12 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/lt/documents/overview/firazyr-epar-summary-public_lt.pdf)

magyar (HU) (97.77 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/hu/documents/overview/firazyr-epar-summary-public_hu.pdf)

Malti (MT) (114.66 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/mt/documents/overview/firazyr-epar-summary-public_mt.pdf)

Nederlands (NL) (77.22 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/nl/documents/overview/firazyr-epar-summary-public_nl.pdf)

polski (PL) (102.29 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/pl/documents/overview/firazyr-epar-summary-public_pl.pdf)

português (PT) (77.49 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/pt/documents/overview/firazyr-epar-summary-public_pt.pdf)

română (RO) (98.77 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/ro/documents/overview/firazyr-epar-summary-public_ro.pdf)

slovenčina (SK) (101.42 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/sk/documents/overview/firazyr-epar-summary-public_sk.pdf)

slovenščina (SL) (96.8 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/sl/documents/overview/firazyr-epar-summary-public_sl.pdf)

Suomi (FI) (76.41 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/fi/documents/overview/firazyr-epar-summary-public_fi.pdf)

svenska (SV) (76.84 KB - PDF)

**First published:**

14/07/2008

**Last updated:**

06/12/2017

[View](/sv/documents/overview/firazyr-epar-summary-public_sv.pdf)

Firazyr : EPAR - Risk management plan

English (EN) (704.61 KB - PDF)

**First published:** 15/10/2025

[View](/en/documents/rmp/firazyr-epar-risk-management-plan_en.pdf)

## Product information

Firazyr : EPAR - Product information

English (EN) (579.11 KB - PDF)

**First published:** 14/07/2009

**Last updated:** 15/10/2025

[View](/en/documents/product-information/firazyr-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-25)

български (BG) (783.8 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/bg/documents/product-information/firazyr-epar-product-information_bg.pdf)

español (ES) (502.46 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/es/documents/product-information/firazyr-epar-product-information_es.pdf)

čeština (CS) (899.86 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/cs/documents/product-information/firazyr-epar-product-information_cs.pdf)

dansk (DA) (539.7 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/da/documents/product-information/firazyr-epar-product-information_da.pdf)

Deutsch (DE) (558.83 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/de/documents/product-information/firazyr-epar-product-information_de.pdf)

eesti keel (ET) (616.67 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/et/documents/product-information/firazyr-epar-product-information_et.pdf)

ελληνικά (EL) (932.39 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/el/documents/product-information/firazyr-epar-product-information_el.pdf)

français (FR) (513.6 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/fr/documents/product-information/firazyr-epar-product-information_fr.pdf)

hrvatski (HR) (699.77 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/hr/documents/product-information/firazyr-epar-product-information_hr.pdf)

íslenska (IS) (499.97 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/is/documents/product-information/firazyr-epar-product-information_is.pdf)

italiano (IT) (543.33 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/it/documents/product-information/firazyr-epar-product-information_it.pdf)

latviešu valoda (LV) (780.05 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/lv/documents/product-information/firazyr-epar-product-information_lv.pdf)

lietuvių kalba (LT) (776.02 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/lt/documents/product-information/firazyr-epar-product-information_lt.pdf)

magyar (HU) (728.04 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/hu/documents/product-information/firazyr-epar-product-information_hu.pdf)

Malti (MT) (757.19 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/mt/documents/product-information/firazyr-epar-product-information_mt.pdf)

Nederlands (NL) (504.22 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/nl/documents/product-information/firazyr-epar-product-information_nl.pdf)

norsk (NO) (490.36 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/no/documents/product-information/firazyr-epar-product-information_no.pdf)

polski (PL) (794.81 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/pl/documents/product-information/firazyr-epar-product-information_pl.pdf)

português (PT) (507.83 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/pt/documents/product-information/firazyr-epar-product-information_pt.pdf)

română (RO) (781.66 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/ro/documents/product-information/firazyr-epar-product-information_ro.pdf)

slovenčina (SK) (807.44 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/sk/documents/product-information/firazyr-epar-product-information_sk.pdf)

slovenščina (SL) (759.07 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/sl/documents/product-information/firazyr-epar-product-information_sl.pdf)

Suomi (FI) (501.71 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/fi/documents/product-information/firazyr-epar-product-information_fi.pdf)

svenska (SV) (499.39 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

15/10/2025

[View](/sv/documents/product-information/firazyr-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0061 04/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Firazyr : EPAR - All authorised presentations

English (EN) (21.39 KB - PDF)

**First published:** 01/12/2008

**Last updated:** 01/12/2020

[View](/en/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-23)

български (BG) (54.07 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/bg/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_bg.pdf)

español (ES) (46.52 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/es/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_es.pdf)

čeština (CS) (50.57 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/cs/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (49.73 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/da/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.12 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/de/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (45.71 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/et/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (50.45 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/el/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_el.pdf)

français (FR) (47.85 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/fr/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (49.04 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/hr/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (49.13 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/is/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.14 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/it/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (49.73 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/lv/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (49.15 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/lt/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (52.43 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/hu/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (50.78 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/mt/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (45.25 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/nl/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (49.21 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/no/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_no.pdf)

polski (PL) (51.61 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/pl/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_pl.pdf)

português (PT) (48.01 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/pt/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_pt.pdf)

română (RO) (48.58 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/ro/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (50.26 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/sk/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (46.79 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/sl/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (43.81 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/fi/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.33 KB - PDF)

**First published:**

01/12/2008

**Last updated:**

01/12/2020

[View](/sv/documents/all-authorised-presentations/firazyr-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Firazyr Active substance icatibant International non-proprietary name (INN) or common name icatibant Therapeutic area (MeSH) Angioedemas, Hereditary Anatomical therapeutic chemical (ATC) code B06AC02

### Pharmacotherapeutic group

Cardiac therapy

### Therapeutic indication

Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

## Authorisation details

EMA product number EMEA/H/C/000899 Marketing authorisation holder

Takeda Pharmaceuticals International AG

50-58 Baggot Street Lower

Opinion adopted 24/04/2008 Marketing authorisation issued 11/07/2008 Revision 26

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Firazyr : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (255.32 KB - PDF)

**First published:** 14/07/2009

**Last updated:** 15/10/2025

[View](/en/documents/procedural-steps-after/firazyr-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf-0)

Firazyr-H-C-000899-P46-01100-1 : EPAR - Assessment report

Reference Number: EMADOC-1700519818-1877468

English (EN) (241.23 KB - PDF)

**First published:** 07/05/2025

[View](/en/documents/variation-report/firazyr-h-c-000899-p46-01100-1-epar-assessment-report_en.pdf)

Firazyr-H-C-000899-P46-036 : EPAR - Assessment report

Adopted

Reference Number: EMA/285123/2024

English (EN) (336.23 KB - PDF)

**First published:** 19/06/2024

[View](/en/documents/variation-report/firazyr-h-c-000899-p46-036-epar-assessment-report_en.pdf)

Firazyr-H-C-899-P46-35 : EPAR - Assessment report

Adopted

Reference Number: EMA/113530/2023

English (EN) (254.94 KB - PDF)

**First published:** 28/04/2023

[View](/en/documents/variation-report/firazyr-h-c-899-p46-35-epar-assessment-report_en.pdf)

Firazyr-H-C-PSUSA-00001714-201707 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/271222/2018

English (EN) (121.29 KB - PDF)

**First published:** 02/05/2018

**Last updated:** 02/05/2018

[View](/en/documents/scientific-conclusion/firazyr-h-c-psusa-00001714-201707-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Firazyr-H-C-899-II-0034-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/702004/2017

English (EN) (1.5 MB - PDF)

**First published:** 09/02/2018

**Last updated:** 09/02/2018

[View](/en/documents/variation-report/firazyr-h-c-899-ii-0034-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Firazyr (II-34-G)

Reference Number: EMA/CHMP/590603/2017

English (EN) (67.15 KB - PDF)

**First published:** 15/09/2017

**Last updated:** 15/09/2017

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-firazyr-ii-34-g_en.pdf)

Firazyr-H-C-899-II-0024-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/57346/2014

English (EN) (1.12 MB - PDF)

**First published:** 12/06/2014

**Last updated:** 12/06/2014

[View](/en/documents/variation-report/firazyr-h-c-899-ii-0024-g-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Firazyr : EPAR - Public assessment report

English (EN) (783.5 KB - PDF)

**First published:** 21/07/2008

**Last updated:** 21/07/2008

[View](/en/documents/assessment-report/firazyr-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use summary of positive opinion for Firazyr

Reference Number: EMEA/CHMP/197104/2008

English (EN) (32.39 KB - PDF)

**First published:** 28/04/2008

**Last updated:** 28/04/2008

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-firazyr_en.pdf)

#### News on Firazyr

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11 to 14 September 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2017) 15/09/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 February 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-february-2014) 21/02/2014

#### More information on Firazyr

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-03-133) on 17 February 2003. Firazyr was withdrawn from the Community register of orphan medicinal products in July 2020 at the end of the 12-year period of market exclusivity.

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Firazyr : EPAR - Product information - tracked changes

English (EN) (401.06 KB - DOCX)

**First published:** 15/10/2025

[View](/en/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-449)

български (BG) (406.84 KB - DOCX)

**First published:**

15/10/2025

[View](/bg/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_bg.docx)

español (ES) (359.12 KB - DOCX)

**First published:**

15/10/2025

[View](/es/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_es.docx)

čeština (CS) (444.74 KB - DOCX)

**First published:**

15/10/2025

[View](/cs/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (389.8 KB - DOCX)

**First published:**

15/10/2025

[View](/da/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (411.31 KB - DOCX)

**First published:**

15/10/2025

[View](/de/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (388.87 KB - DOCX)

**First published:**

15/10/2025

[View](/et/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (427.2 KB - DOCX)

**First published:**

15/10/2025

[View](/el/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_el.docx)

français (FR) (406.68 KB - DOCX)

**First published:**

15/10/2025

[View](/fr/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (399.52 KB - DOCX)

**First published:**

15/10/2025

[View](/hr/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (398.57 KB - DOCX)

**First published:**

15/10/2025

[View](/is/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_is.docx)

italiano (IT) (443.09 KB - DOCX)

**First published:**

15/10/2025

[View](/it/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (428.28 KB - DOCX)

**First published:**

15/10/2025

[View](/lv/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (351.29 KB - DOCX)

**First published:**

15/10/2025

[View](/lt/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (412.17 KB - DOCX)

**First published:**

15/10/2025

[View](/hu/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (392 KB - DOCX)

**First published:**

15/10/2025

[View](/mt/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (406.97 KB - DOCX)

**First published:**

15/10/2025

[View](/nl/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (388.18 KB - DOCX)

**First published:**

15/10/2025

[View](/no/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_no.docx)

polski (PL) (412.49 KB - DOCX)

**First published:**

15/10/2025

[View](/pl/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_pl.docx)

português (PT) (398 KB - DOCX)

**First published:**

15/10/2025

[View](/pt/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_pt.docx)

română (RO) (372.13 KB - DOCX)

**First published:**

15/10/2025

[View](/ro/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (408.95 KB - DOCX)

**First published:**

15/10/2025

[View](/sk/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (393.53 KB - DOCX)

**First published:**

15/10/2025

[View](/sl/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (402.75 KB - DOCX)

**First published:**

15/10/2025

[View](/fi/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (391.81 KB - DOCX)

**First published:**

15/10/2025

[View](/sv/documents/product-information-tracked-changes/firazyr-epar-product-information-tracked-changes_sv.docx)

#### More information on Firazyr

- [EMEA-000408-PIP01-08-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000408-pip01-08-m05)
- [EMEA-000408-PIP02-12 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000408-pip02-12)
- [Firazyr - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/firazyr)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 15/10/2025

## Share this page

[Back to top](#main-content)